Sun Pharma clarifies $10 bn Organon acquisition report, calls it 'speculative in nature'

Sun Pharma has addressed speculation regarding a potential $10 billion acquisition of US firm Organon. The Indian drugmaker stated the reports are speculative and no material event requires disclosure. Sun Pharma adheres to high governance standards. Organon, focused on women's health and biosimilars, was spun off from Merck in 2021.